D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$751M |
| 2 |
Advanced Micro Devices
AMD
|
+$751M |
| 3 |
Micron Technology
MU
|
+$426M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$363M |
| 5 |
ExxonMobil
XOM
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$546M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$485M |
| 3 |
VMW
VMware, Inc
VMW
|
+$393M |
| 4 |
Microsoft
MSFT
|
+$336M |
| 5 |
UnitedHealth
UNH
|
+$303M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.03% |
| 2 | Consumer Discretionary | 9.51% |
| 3 | Healthcare | 5.76% |
| 4 | Financials | 5.47% |
| 5 | Communication Services | 4.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
CALL
Levi Strauss
LEVI
$9.8B
| $3.68M | ﹤0.01% |
222,400
| – | – |
|
2027
Clearwater Paper
CLW
$282M
| $3.68M | ﹤0.01% |
101,807
+51,066
| +101% | +$1.83M |
|
2028
Kodiak Sciences
KOD
$2.52B
| $3.68M | ﹤0.01% |
1,208,973
+212,840
| +21% | +$473K |
|
2029
PUT
Teva Pharmaceuticals
TEVA
$36.9B
| $3.67M | ﹤0.01% |
351,600
-120,000
| -25% | -$1.12M |
|
2030
Vanguard Total Stock Market ETF
VTI
$656B
| $3.67M | ﹤0.01% |
+15,469
| New | +$3.42M |
|
2031
Zions Bancorporation
ZION
$10.1B
| $3.67M | ﹤0.01% |
83,616
+69,556
| +495% | +$2.51M |
|
2032
Cummins
CMI
$88.5B
| $3.65M | ﹤0.01% |
15,245
+3,069
| +25% | +$698K |
|
2033
Antero Midstream
AM
$10.3B
| $3.65M | ﹤0.01% |
291,343
+43,182
| +17% | +$544K |
|
2034
Vericel Corp
VCEL
$2.39B
| $3.65M | ﹤0.01% |
102,439
-76,750
| -43% | -$2.67M |
|
2035
SAP
SAP
$209B
| $3.64M | ﹤0.01% |
+23,551
| New | +$3.41M |
|
2036
Toyota
TM
$221B
| $3.64M | ﹤0.01% |
+19,844
| New | +$3.62M |
|
2037
Olin
OLN
$2.44B
| $3.63M | ﹤0.01% |
67,276
-16,400
| -20% | -$785K |
|
|
ESPR
2038
DELISTED
Esperion Therapeutics
ESPR
| $3.63M | ﹤0.01% |
+1,213,203
| New | +$1.57M |
|
2039
W.R. Berkley
WRB
$28.3B
| $3.63M | ﹤0.01% |
76,893
-270,752
| -78% | -$12.3M |
|
|
RVNC
2040
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.62M | ﹤0.01% |
411,750
-370,266
| -47% | -$3.03M |
|
2041
PUT
TD Synnex
SNX
$19.8B
| $3.62M | ﹤0.01% |
+33,600
| New | +$3.3M |
|
2042
Madrigal Pharmaceuticals
MDGL
$12.4B
| $3.61M | ﹤0.01% |
15,622
+9,708
| +164% | +$1.7M |
|
2043
Microvast
MVST
$256M
| $3.61M | ﹤0.01% |
2,580,479
+428,093
| +20% | +$574K |
|
2044
Gevo
GEVO
$363M
| $3.61M | ﹤0.01% |
3,107,884
-230,299
| -7% | -$263K |
|
2045
Alto Ingredients
ALTO
$345M
| $3.6M | ﹤0.01% |
1,354,886
+497,854
| +58% | +$1.59M |
|
2046
Camden Property Trust
CPT
$11.4B
| $3.59M | ﹤0.01% |
36,181
-76,128
| -68% | -$7.05M |
|
2047
Jefferies Financial Group
JEF
$13.2B
| $3.58M | ﹤0.01% |
88,715
-140,679
| -61% | -$4.98M |
|
|
HCP
2048
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $3.58M | ﹤0.01% |
151,520
-124,414
| -45% | -$2.7M |
|
2049
Exelon
EXC
$48.4B
| $3.58M | ﹤0.01% |
99,763
-49,849
| -33% | -$1.92M |
|
|
SEE
2050
PUT
DELISTED
Sealed Air
SEE
| $3.58M | ﹤0.01% |
98,000
-23,900
| -20% | -$784K |
|
Similar funds
D.E. Shaw & Co's Q4 2023 Portfolio in Review
As of Q4 2023, D.E. Shaw & Co held 4,806 positions worth $114B, up 19% from $95.8B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
D.E. Shaw & Co's Q4 2023 filing shows 575 new, 1,549 increased, 1,464 reduced and 527 closed positions. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 2,424,593 shares worth $188M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $546M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- D.E. Shaw & Co's largest Q4 2023 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 2,424,593 shares worth $188M.
- D.E. Shaw & Co added most to Netflix in Q4 2023, an estimated $751M increase.
- D.E. Shaw & Co's biggest Q4 2023 reduction was Microsoft, cutting an estimated $336M.
- D.E. Shaw & Co fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $546M.
- D.E. Shaw & Co's ten largest holdings make up 12% of its $114B portfolio in Q4 2023.
- D.E. Shaw & Co opened 575 new positions and closed 527 in Q4 2023.
- D.E. Shaw & Co's portfolio value rose 19% quarter-over-quarter to $114B.
Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.